DMD DiLab, Inc.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on August 4, 2005; DOI: 10.1124/dmd.105.004630


0090-9556/05/3311-1688-1699$20.00
DMD 33:1688-1699, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.004630v1
33/11/1688    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shaffer, C. L.
Right arrow Articles by Yee, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shaffer, C. L.
Right arrow Articles by Yee, S.

BIOTRANSFORMATION OF A GABAA RECEPTOR PARTIAL AGONIST IN SPRAGUE-DAWLEY RATS AND CYNOMOLGUS MONKEYS: IDENTIFICATION OF TWO UNIQUE N-CARBAMOYL METABOLITES

Christopher L. Shaffer, Mithat Gunduz, Thomas N. O'Connell, R. Scott Obach, and Shiyin Yee1

Departments of Pharmacokinetics, Pharmacodynamics and Metabolism (C.L.S., M.G., R.S.O., S.Y.) and Exploratory Medicinal Sciences (T.N.O.), Pfizer Global Research and Development, Groton/New London Laboratories, Pfizer Inc., Groton, Connecticut

The absorption, metabolism, and excretion of N-[3-fluoro-4-[2-(propylamino)ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo-1H-indole-3-carboxamide monomethanesulfonate (1), a GABAA receptor partial agonist potentially useful in treating generalized anxiety disorder, have been evaluated in both Sprague-Dawley rats and cynomolgus monkeys using [14C]1. In both species, mass balance was achieved within 48 h postdose, with the majority of drug-related material excreted within the feces; the clearance of 1 in each species had both metabolic and renal components. In addition to the metabolites produced by aliphatic hydroxylation and/or N-dealkylation of 1, two unique metabolites were detected: a putative carbamic acid (M7) in rat plasma and monkey bile, and an N-carbamoyl glucuronide (M8) in both rat and monkey bile. Metabolite M8 was structurally deciphered by liquid chromatographytandem mass spectrometry and NMR, and was readily generated in vitro upon incubation of [14C]1 with rat liver microsomes fortified with uridine 5'-diphosphoglucuronic acid trisodium salt and alamethicin under a CO2 atmosphere. Treatment of M8 with ß-glucuronidase afforded 1 directly. The presence of M8 in bile and its notable absence from other matrices suggests the enterohepatic cycling of 1 via M8. Although the structure of M7 was not elucidated unequivocally due to its inability to be formed in vitro and its minimal absolute quantities in limited biological matrices, data herein clearly support its structural rationalization. Furthermore, since M7 is the precursor of M8, detection of M8 is indirect evidence of its existence. It is proposed that M7 arises from an equilibrium between 1 and dissolved CO2-equivalents both in vivo and in vitro, similar to carbamino bonds observed in hemoglobin and certain amino acids, respectively.


Address correspondence to: Dr. Christopher L. Shaffer, Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Groton/New London Laboratories, Pfizer Inc., Eastern Point Road, MS 4075, Groton, CT 06340. E-mail: Christopher.L.Shaffer{at}pfizer.com




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
C. L. Shaffer, M. Gunduz, A. D. Vaz, K. Venkatakrishnan, and A. H. Burstein
Metabolism and Disposition of a {gamma}-Aminobutyric Acid Type A Receptor Partial Agonist in Humans
Drug Metab. Dispos., April 1, 2008; 36(4): 655 - 662.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
K. Venkatakrishnan, E. Tseng, F. R. Nelson, H. Rollema, J. L. French, I. V. Kaplan, W. E. Horner, and M. A. Gibbs
Central Nervous System Pharmacokinetics of the Mdr1 P-Glycoprotein Substrate CP-615,003: Intersite Differences and Implications for Human Receptor Occupancy Projections from Cerebrospinal Fluid Exposures
Drug Metab. Dispos., August 1, 2007; 35(8): 1341 - 1349.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.